Literature DB >> 18703536

Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction.

Justin F X Ainscough1, Mark J Drinkhill, Alicia Sedo, Neil A Turner, David A Brooke, Anthony J Balmforth, Stephen G Ball.   

Abstract

AIMS: Sustained hypertension leads to cardiac hypertrophy that can progress, through pathological remodelling, to heart failure. Abnormality of the renin-angiotensin system (RAS) has been strongly implicated in this process. Although hypertrophy in human is an established risk factor independent of blood pressure (BP), separation of remodelling in response to local cues within the differentiated myocardium from that related to pressure overload is unresolved. This study aimed to clarify the role of local RAS activity, specifically in the adult heart, in modulating cardiac hypertrophy and pathological remodelling. METHODS AND
RESULTS: Transgenic mice with inducible cardiomyocyte-specific expression of a wild-type or N111G mutant form of the human angiotensin II (Ang II) type-1 receptor (hAT1R) were generated. The wild-type receptor is primarily stimulated by Ang II. In contrast, the N111G receptor can also be fully stimulated by the Ang II derivative, Ang IV, at levels that do not stimulate the wild-type receptor. The unique properties of these models were used to investigate the myocardial growth, remodelling and functional responses to hAT1R stimulation, specifically in adult cardiomyocytes, under normal conditions and following Ang IV infusion. Low-level expression of wild-type or N111G hAT1R at the cardiomyocyte membrane, from the onset of adolescence, induced enhanced myocyte growth and associated cardiac hypertrophy in the adult. This was not associated with change in resting BP or heart rate, measured by longitudinal telemetric analysis, and did not progress to pathological remodelling or heart failure. However, selective activation of cardiomyocyte-specific N111G receptors by Ang IV peptide infusion induced adverse ventricular remodelling within 4 weeks. This was characterized by increased interstitial fibrosis, dilatation of the left ventricle, and impaired cardiac function.
CONCLUSION: Low-level local AT1R activity in differentiated myocardium causes compensated cardiac hypertrophy, that is, increased myocardial mass but with the retention of normal function, whereas short-term increased stimulation induces cardiac dysfunction with dilatation, reduced ejection fraction, and increased fibrosis in the absence of change in systemic BP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18703536     DOI: 10.1093/cvr/cvn230

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  47 in total

1.  LOX-1 abrogation reduces cardiac hypertrophy and collagen accumulation following chronic ischemia in the mouse.

Authors:  J Lu; X Wang; W Wang; H Muniyappa; C Hu; S Mitra; B Long; K Das; J L Mehta
Journal:  Gene Ther       Date:  2011-09-22       Impact factor: 5.250

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

3.  Inhibition of urea transporter ameliorates uremic cardiomyopathy in chronic kidney disease.

Authors:  Akihiro Kuma; Xiaonan H Wang; Janet D Klein; Lin Tan; Nawazish Naqvi; Fitra Rianto; Ying Huang; Manshu Yu; Jeff M Sands
Journal:  FASEB J       Date:  2020-05-04       Impact factor: 5.191

4.  Pharmacologic effects of 2-methoxyestradiol on angiotensin type 1 receptor down-regulation in rat liver epithelial and aortic smooth muscle cells.

Authors:  Sivaramakrishna Koganti; Russell Snyder; Thomas Thekkumkara
Journal:  Gend Med       Date:  2012-02-25

5.  Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.

Authors:  Chetan P Hans; Yumei Feng; Amarjit S Naura; Dana Troxclair; Mourad Zerfaoui; Danish Siddiqui; Ju Jihang; Hogyoung Kim; Alan D Kaye; Khalid Matrougui; Eric Lazartigues; A Hamid Boulares
Journal:  Cardiovasc Pathol       Date:  2010-05-07       Impact factor: 2.185

6.  Polydatin prevents angiotensin II-induced cardiac hypertrophy and myocardial superoxide generation.

Authors:  Qi Zhang; Yingying Tan; Nan Zhang; Fanrong Yao
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-07

Review 7.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

Review 8.  G-Protein-Coupled Receptors in Heart Disease.

Authors:  Jialu Wang; Clarice Gareri; Howard A Rockman
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

Review 9.  Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance.

Authors:  Timothy D O'Connell; Brian C Jensen; Anthony J Baker; Paul C Simpson
Journal:  Pharmacol Rev       Date:  2013-12-24       Impact factor: 25.468

10.  Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy.

Authors:  Hong Yue; Wei Li; Russell Desnoyer; Sadashiva S Karnik
Journal:  Cardiovasc Res       Date:  2010-01-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.